To examine the epidemiology and mechanistic underpinnings of heightened cardiovascular disease (CVD) risk among women living with HIV (WLHIV) in North America and Europe.
INTRODUCTION
Availability of effective antiretroviral therapy (ART) across North America and Europe has, in these regions, transformed HIV into a chronic disease with extended life expectancy [1, 2] . Progress notwithstanding, women living with HIV (WLHIV) in these regions evidence high incidence rates of cardiovascular disease (CVD) events, not dissimilar from those of compatriot men living with HIV (MLHIV) [3] [4] [5] [6] [7] [8] . WLHIV in North America and Europe, as compared with women without HIV residing in these regions, confront a 2-4-fold increased relative risk for myocardial infarction (MI), stroke, and heart failure [3] [4] [5] [6] [7] [8] . In this review, we will consider large-scale epidemiologic studies situating the scope of the problem of heightened CVD risk among WLHIV in North America and Europe. Next, drawing from both epidemiologic and physiologic studies, we will consider sex-specific mechanisms underlying this risk. Finally, we will address future directions for HIV-associated CVD risk research relevant to women and ways research findings may be applied towards improving preventive cardiac care for WLHIV globally.
Risk of myocardial infarction
Triant et al. published one of the earliest large-scale epidemiologic studies offering sex-stratified analyses of MI risk among individuals with and without HIV. As part of this study, 3851 individuals with HIV (30.4% women) and 1,044,589 individuals without HIV (59.1% women) in the US Partners HealthCare System were followed from 1996 to 2004. Unadjusted MI rates by sex and HIV status were 12.71/ 1000 person-years among WLHIV, as compared with rates of 4.88/1000 person-years for women without HIV, 10.48/1000 person-years for MLHIV, and 11.44/1000 person-years for men without HIV. Adjusted relative risk assessments for MI by comparator group (adjusted for traditional CVD risk factors) were 1.75 [95% confidence interval (CI) 1.51-2.02] HIV vs. non-HIV; 2.98 (95% CI 2.33-3.75) for WLHIV vs. women without HIV; and 1.40 (95% CI 1.16-1.67) for MLHIV vs. men without HIV [3] . Data from subsequent large-scale epidemiologic studies with later follow-up periods conducted in the United States and in Europe corroborated similar trends -namely, a higher relative risk of MI among women with vs. without HIV as compared to that among men with vs. without HIV [4, 5, 9, 10] . Moreover, sex-and age-stratified analyses from United States and European studies revealed that among WLHIV (vs. age-matched women without HIV), the most prominently increased relative risk of MI was in women aged below 50 years [4, 5] .
Risk of stroke
Chow et al. published seminal large-scale epidemiologic studies offering sex-stratified analyses of ischemic and hemorrhagic stroke risk among individuals with and without HIV. In one study, 4308 individuals with HIV (31% women) and 32,423 individuals without HIV (10 : 1 matched), receiving care in the US Partners HealthCare System, were followed from 1996 to 2009. Unadjusted ischemic stroke incidence rates by sex and HIV status were 5.02/1000 personyears for WLHIV, 2.31/1000 person-years for women without HIV, 5.38/1000 person-years for MLHIV, and 4.59/1000 person-years for men without HIV. The unadjusted hazard ratios for ischemic stroke by comparator groups were 1.40 (95% CI 1.17-1.69) HIV vs. non-HIV; 2.16 (95% CI 1.53-3.04) WLHIV vs. women without HIV; and 1.18 (95% CI 0.95-1.47) MLHIV vs. men without HIV. The adjusted hazard ratios for ischemic stroke in HIV (adjusted for stroke risk factors) were also significantly increased among women, but not among men [6] . Sex and agestratified analyses revealed that among WLHIV (vs. age-matched women without HIV), the most prominently increased hazard ratios for ischemic stroke were among women aged below 55 years [7] . With respect to hemorrhagic stroke, Chow et al. followed 4251 individuals with HIV (31% women) and 35 CVD risk research relevant to women's health requires conscientious study design, with plans to: enroll and retain adequate numbers of women participants; assess sex-specific CVD risk factors; and present well-powered sex-stratified analyses on major scientific questions of interest.
The ongoing international REPRIEVE trial, testing whether statin therapy prevents major adverse cardiovascular events in HIV, encourages WLHIV to participate through the Follow YOUR Heart Campaign and incorporates sex-specific objectives into the main study protocol.
Reducing women's risk of HIV-associated CVD will require investing in targeted research across low-and high-resource regions globally and translating acquired knowledge into CVD risk prediction algorithms and preventive care guidelines tailored to women aging with HIV.
Risk of heart failure
To date, no large-scale epidemiologic studies have presented sex-stratified analyses of newly diagnosed heart failure among individuals with and without HIV. However, juxtaposition of separate cohort studies focused on incident heart failure in men or women with and without HIV permits for comparative inferences. Butt et al. first analyzed the risk of incident heart failure among men with and without HIV in the US Veterans Aging Cohort Study Virtual Cohort and the Large Health Study of Veteran Enrollees. As part of this study, 2391 men with HIV and 6095 men without HIV were followed from 2000 to 2007. The adjusted hazard ratio for heart failure among men with vs. without HIV (adjusted for heart failure risk factors) was 1.81 (95% CI 1.39-2.36) [11] . Freiberg et al. returned to the US Veterans Aging Cohort Study Virtual Cohort (97% men) to examine the predominant types of heart failure among individuals with HIV. In this study, 98, 015 participants, 32.2% with HIV, were followed from 2003 to 2012. Among those MLHIV who developed heart failure, 34.6% developed heart failure with preserved ejection fraction (EF 50%), 15.5% developed borderline heart failure with preserved ejection fraction (EF 40-49%), 37.1% developed heart failure with reduced ejection fraction (EF < 40%), and 12.8% developed heart failure of unknown type. Moreover, in this study, the relative risk of all three types of heart failure was increased by approximately 20-60% among individuals with HIV, even after adjustment for heart failure risk factors [12] . Most recently, Janjua et al. led a largescale epidemiologic study focused on 1388 WLHIV and 13,781 women without HIV (10 : 1 matched) receiving clinical care in the US Partners HealthCare System. Among WLHIV, the heart failure incidence rate was approximately four times higher than that among women without HIV (2.5% cumulative or 0.27%/year for WLHIV vs. 0.74% cumulative or 0.07%/year for women without HIV). Among those WLHIV with heart failure, heart failure with preserved ejection fraction was far and away the predominant subtype (71%) [13 & ].
SEX-SPECIFIC MECHANISMS UNDERLYING HEIGHTENED CARDIOVASCULAR DISEASE RISK AMONG WOMEN LIVING WITH HIV
Broadly, traditional cardiometabolic risk factors, behavioral risk factors, and heightened systemic immune activation/inflammation contribute synergistically to the heightened risk of HIV-associated CVD [14, 15] . ART exerts complex and regimenspecific effects on nonbehavioral CVD risk factors, exacerbating select metabolic conditions and concomitantly dampening (without normalizing) indices of systemic immune activation/inflammation [14, 15] . Discussed below are special considerations for WLHIV. Among WLHIV, female sex and endogenous sex hormone production influence both nonbehavioral cardiometabolic risk factors and, importantly, patterns of systemic immune activation/inflammation. WLHIV in North America and Europe may also experience heightened CVD risk in relation to a relatively increased prevalence of behavioral/psychosocial CVD risk factors and suboptimal therapeutic targeting of known traditional cardiometabolic risk factors (Fig. 1) .
Traditional cardiometabolic risk factors
Dyslipidemia, dysglycemia, and hypertension (HTN) are well established traditional cardiometabolic risk factors for MI, stroke, and heart failure in the general population [16] . The question of how the cardiometabolic risk profile of WLHIV in North America and Europe compares to that among compatriot women without HIV, MLHIV, and men without HIV poses unique challenges. First, lifestyle choices, rooted in regional custom, influence the prevalence of traditional cardiometabolic risk factors. Second, several large cohort studies focused on WLHIV and MLHIV have purposefully recruited control individuals with similar lifestyle choices so as to isolate the effects of infection and treatment on HIV-associated morbidity. Consequently, the cardiometabolic risk profiles of control individuals in these cohorts may differ distinctly from those of the general population. Finally, few studies in unselected populations compare traditional cardiometabolic risk factors across groups stratified both by HIV status and by sex. Sex-stratified analyses on the prevalence of traditional cardiometabolic risk factors among the large number of patients with and without HIV receiving care in the US Partners Healthcare System have, however, been presented by Triant et al. We may glean insights from these analyses, cognizant that the patterns observed may be regionally specific (urban northeast United States) and not broadly generalizable. Among WLHIV, the prevalence of traditional cardiometabolic risk factors, including HTN, diabetes, and dyslipidemia, tends to be higher than that among women without HIV and just slightly lower than that among MLHIV and men without HIV [3, 4] .
Why might the prevalence of traditional nonbehavioral cardiometabolic risk factors be 'relatively' increased among WLHIV vs. women without HIV compared with among MLHIV vs. men without HIV?
It is possible that sex differences in pharmacokinetics and pharmacodynamics [17, 18] render WLHIV particularly susceptible to ART-induced ectopic fat deposition and/or metabolic dysregulation. Prospective studies comparing differential effects of newly initiated contemporary ART regimens on salient metabolic parameters among ART-naive women vs. men with HIV could test this hypothesis. A second consideration is that among WLHIV (vs. women without HIV), lower-level and/ or less sustained endogenous sex hormone production may predispose to the development of cardiometabolic risk factors (see below the sub-section, 'Altered endogenous sex hormone production and effects on cardiometabolic parameters and systemic immune activation/inflammation').
Increased systemic immune activation and inflammation
HIV infection depresses immune function while simultaneously stimulating several systemic immune/ inflammatory pathways relevant to carotid/coronary atherosclerosis and myocardial fibrosis [15, 19] . Activated immune cells (particularly monocytesturned-macrophages, but also T cells and other types of immune cells) participate meaningfully in atherosclerotic plaque formation and pathologic plaque remodeling [20] . Several physiology studies performed in all-male or predominantly male (>90% male) cohorts have revealed relationships between systemic markers of monocyte activation (soluble CD163, sCD163; soluble CD14, sCD14) and surrogates of atherosclerotic CVD (ASCVD) risk including subclinical carotid artery atherosclerosis [21] , aortic inflammation [22, 23] , subclinical coronary atherosclerotic plaque [24] [25] [26] , and pathologically remodeled coronary atherosclerotic plaque [27, 28] . Separate physiology studies among WLHIV have confirmed parallel relationships between systemic immune activation markers and ASCVD risk surrogates, including subclinical carotid atherosclerosis [29] [30] [31] and the percentage of noncalcified coronary atherosclerotic plaque [32] . Cells of monocyte/ macrophage lineage may also engender myocardial edema and fibrosis, presaging diastolic dysfunction and heart failure with preserved ejection fraction [33, 34] . Findings from an endomyocardial biopsy study suggest that among individuals with HIV, myocardial fibrosis is increased in association with in-situ CD163 þ macrophage infiltration and circulating levels of the monocyte activation marker sCD163 [35] . Moreover, mixed-sex cardiac MRI studies led by Holloway et al. [36] and Thiara et al. [37] confirmed among asymptomatic individuals with HIV an increased prevalence and extent of myocardial fibrosis in relation to diastolic dysfunction.
Among WLHIV, several indices of systemic immune activation are particularly increased. Fitch et al. [32] showed that levels of systemic monocyte activation markers relevant to HIV-associated CVD (sCD163, sCD14) are highest among asymptomatic WLHIV, as compared with levels among women without HIV, MLHIV, and men without HIV. In a two-group comparison of women with vs. without HIV, Alcaide et al. [38] further demonstrated increased T cell activation and exhaustion among ART-treated WLHIV. There is a plausible biologic basis for heightened systemic immune activation/ inflammation among WLHIV relating to sexspecific expression of key toll-like receptors (TLRs) and enhanced innate immune response to HIV infection [39] . Acutely, innate immune hyperresponsiveness to HIV may enable women to better suppress the virus. Over time, this sex-specific response may be maladaptive, resulting in chronic immune cell activation and immunosenescence [39] . Another possible explanation for heightened systemic immune activation/inflammation among WLHIV relates to the traditional and nontraditional cardiometabolic risk profile characteristic of this population. Behavioral risk factors (e.g. cigarette smoking, cocaine use) and comorbid conditions (e.g. hepatitis C, depression) among WLHIV in North America and Europe may all be expected to stimulate systemic immune activation and inflammation.
Effects of therapeutic drugs on systemic immune activation markers differ by sex in HIV. Separate US studies among WLHIV and among MLHIV have confirmed that ART dampens select indices of systemic immune activation, albeit not down to levels seen in control individuals [40] [41] [42] . Of note, however, an AIDS Clinical Trials Group study conducted in a resource-limited setting revealed that ART suppresses select indices of systemic immune activation to a lesser degree among WLHIV than among MLHIV [43 && ]. Just as ART exerts immunomodulatory effects in HIV, so too does statin therapy. Several US studies, including the mixed-sex Stopping Atherosclerosis and Treating Unhealthy Bone With Rosuvastatin in HIV (SAT-URN-HIV) study, have shown statins dampen key indices of systemic immune activation among asymptomatic people living with HIV [44] [45] [46] . Intriguingly, in the mixed-sex HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia (INTREPID) trial, pitavastatin (a newer statin which does not tend to have drug-drug interactions with ART) [47] decreased systemic levels of select monocyte activation markers relevant to HIV-associated CVD -more so among WLHIV than among MLHIV [48 & ].
Altered endogenous sex hormone production and effects on cardiometabolic parameters and systemic immune activation/ inflammation After menopause, women see a marked increase in the incidence of CVD risk factors (HTN, diabetes, and dyslipidemia) and CVD (MI, stroke, and heart failure) [49] . Disentangling intertwined effects of chronological and reproductive aging on CVD risk in women has proven challenging [50] [51] [52] . Select findings from large-scale US general population CVD research studies imply, indirectly, that robust and sustained endogenous estrogen production may protect women against CVD. For example, in the Study of Women's Health Across the Nation (SWAN), lower endogeneous estrogen levels among premenopausal/early perimenopausal women predicted increased progression of subclinical atherosclerosis [53] . Further, in the Nurses' Health Study and the Framingham Heart Study, early age at natural menopause related to increased risk of coronary heart disease and ischemic stroke, respectively [54, 55] .
Women living with HIV, however, seem to suffer disproportionately from perturbations along the hypothalamic-pituitary-gonadal axis, resulting in reduced premenopausal endogenous estrogen production and 'possibly' in accelerated reproductive aging en route to terminal menses. Karim et al. [56] showed through an analysis of data from the US Women's Interagency HIV Study (WIHS) that estrogen and androgen levels were reduced among premenopausal WLHIV (vs. age-matched women without HIV). Whether WLHIV experience menopause at an earlier age than women without HIV remains unsettled, despite a rigorous meta-analysis of available studies on the topic [57] . The dilemma in 'defining' menopause among WLHIV has, for years, hindered headway on this question. Traditional reproductive aging classification schemes rely on menstrual history, and also follicle-stimulating hormone and E2 timed to menstrual cycle day 3, and such schemes are ill-suited to women with chronic illness or menstrual irregularity [58, 59] . Among WLHIV, menstrual irregularity is not uncommon. Indeed, in the US WIHS, WLHIV (vs. similarly aged women without HIV) were approximately three times as likely to experience prolonged amenorrhea unrelated to ovarian failure [60] . How, then, to assess reproductive aging in HIV?
Remarkably, the discovery and validation of a novel biomarker for ovarian reserve -antimullerian hormone, or AMH -has ushered in a breakthrough for reproductive aging research in HIV. AMH is a protein encoded by the AMH gene and secreted by ovarian granulosa cells. A woman's remaining egg supply is reflected in AMH levels, and AMH levels become undetectable prior to menopause [61, 62] . Importantly, AMH levels are not cycle-dependent [61] [62] [63] . This lack of cycle dependency is crucial, as visits for female participants in clinical trials cannot always feasibly be timed to the menstrual cycle. Importantly, Scherzer et al. [64 && ] showed that among WLHIV in the WIHS, age-adjusted AMH levels were lower than among women without HIV. Scherzer et al. [65 && ] also demonstrated that among WLHIV, AMH levels predicted age at menopause. Most recently, Looby et al. used menstrual history and AMH levels to subdivide a US cohort of WLHIV into three reproductive aging groups: women with menses and detectable AMH; women with menses and undetectable AMH (reduced ovarian reserve); and women without menses and with undetectable AMH (postmenopause). Reduced ovarian reserve among WLHIV was found to relate to a key CVD risk surrogate -noncalcified coronary atherosclerotic plaque -even after controlling for traditional CVD risk factors including age. Of note, the largest 'step-up' for CVD risk (subclinical noncalcified coronary plaque prevalence) occurred between the first and the second groups. These findings imply that WLHIV with reduced ovarian reserve who still undergo menstrual cycling should not necessarily be considered to harbor low CVD risk. In this study, among WLHIV, markers of systemic immune activation were also noted to increase across progressive categories of reproductive aging [66 & ].
Behavioral and psychosocial cardiovascular disease risk factors and treatment disparities
Cigarette smoking and cocaine use represent known behavioral risk factors for MI, stroke, and heart failure in the general population [16] . In a special population (US Veterans), WLHIV evidenced a 13.5% prevalence of cocaine use -significantly higher than the 3.6% prevalence of cocaine use among women without HIV [10] . Psychosocial CVD risk factors such as depression are also increased among WLHIV (vs. women without) according to both US [70] and European studies [71] . Depression has been shown to relate to measures of CVD risk among WLHIV [70] and CVD event rates among women in the general population [72] . Data on whether WLHIV receive particularly suboptimal medical therapy for known traditional cardiometabolic risk factors or cardiac conditions are conflicting. A US WIHS study suggested that a higher percentage of WLHIV receive targeted therapeutics for known cardiometabolic risk factors as compared with women without HIV [73] . In contrast, a US Partners Healthcare System database study revealed that a lower percentage of WLHIV with heart failure were prescribed standard-of-care therapy as compared with uninfected women with heart failure [13 & ]. Finally, in a different type of comparative study -examining therapeutic targeting of cardiometabolic risk factors among women vs. men with HIV participating in the large-scale European Observational Cohort study, D:A:D -Hatleberg et al. [74] showed that WLHIV were less likely to receive therapeutic interventions for established cardiometabolic risk factors.
FUTURE DIRECTIONS
In HIV-associated CVD research, as in general CVD research, findings from all-male studies should not be assumed to apply to women. CVD risk research relevant to women's health requires conscientious study design, with plans to: enroll and retain adequate numbers of women participants; assess sexspecific CVD risk factors; and present well-powered sex-stratified analyses on major scientific questions of interest [75 & ]. The ongoing international REPRIEVE study (Randomized Trial to Prevent Vascular Events in HIV) will help to elucidate mechanisms of cardiovascular disease risk and risk reduction among women and men with HIV. REPRIEVE is a randomized placebo control trial testing among 6500 individuals with HIV and low-to-moderate traditional CVD risk whether statin therapy (vs. placebo) reduces major adverse cardiovascular events through effects on lipids and/or systemic immune activation [76] . To date, REPRIEVE has engaged more than 100 research sites in the United States, Canada, Brazil, South Africa, Botswana, and Thailand, with additional international sites joining. The evidence-based REPRIEVE Follow YOUR Heart Campaign has been launched to educate WLHIV about heart disease and promote engagement with clinical trials like REPRIEVE [77] . Moreover, objectives to study sex-specific mechanisms of cardiovascular disease risk and risk reduction in HIV have been integrated into the main REPRIEVE protocol.
CONCLUSION
Several forward-looking strategies will help improve cardiovascular health among WLHIV. The first is to invest resources in studying HIV-associated CVD, where it afflicts the most women (Sliwa et al., 'CVD in Women from Sub-Saharan Africa' in this same issue). Cross-comparative studies conducted on mechanisms of CVD risk among WLHIV in Africa, Asia, and South America -and also North America and Europe -may elucidate region-specific genetic susceptibilities to CVD, and also different relative contributions of traditional, behavioral, and psychosocial CVD risk factors. A second key strategy entails revisiting seminal observations from major CVD risk studies conducted among women in the general population [78, 79] and determining the extent to which these apply in HIV. Conversely, CVD research among WLHIV may inform sex-specific CVD research in the general population, as HIV represents an extreme model of the heightened immune reactivity to which women are generally prone. Finally, a third strategy centers on translating knowledge acquired from patient-oriented research into tailored CVD risk prediction algorithms and preventive care guidelines clinically relevant to the approximately 17 million women aging with HIV globally.
